The effect of peripheral blood cell score on the prognosis of multiple myeloma patients treated with bortezomib

This study aims to evaluate the prognostic effect of peripheral blood cells in multiple myeloma (MM) patients treated with bortezomib. The clinical data of 155 newly diagnosed MM patients in two blood disease treatment centers from January 2014 to December 2016 were retrospectively studied. All pati...

Full description

Saved in:
Bibliographic Details
Published in:Zhōnghuá xuèyèxué zázhì 2020-09, Vol.41 (9), p.756-761
Main Authors: Qiu, L, Han, X Y, He, D H, Zhu, F, Zhao, Y, Zhu, W W, Zheng, G F, Yang, Y, Wu, W W, Cai, Z, Yang, X C, He, J S
Format: Article
Language:Chinese
Subjects:
Blood Cells
Bortezomib - therapeutic use
Disease-Free Survival
Humans
Multiple Myeloma - drug therapy
Prognosis
Retrospective Studies
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aims to evaluate the prognostic effect of peripheral blood cells in multiple myeloma (MM) patients treated with bortezomib. The clinical data of 155 newly diagnosed MM patients in two blood disease treatment centers from January 2014 to December 2016 were retrospectively studied. All patients received bortezomib as the first-line treatment. The results of the peripheral blood cell counts, including absolute neutrophil count, absolute monocyte count (AMC) , hemoglobin level, mean corpuscular volume (MCV) , and platelet count, and other clinical features were analyzed. AMC (>0.6×10(9)/L) , MCV (>99.1 fl) , and platelet count (
ISSN:0253-2727
DOI:10.3760/cma.j.issn.0253-2727.2020.09.009